213 related articles for article (PubMed ID: 25649031)
1. Use of the nuclear matrix protein 22 Bladder Chek test™ in the diagnosis of residual urothelial cancer before a second transurethral resection of bladder cancer.
Balci M; Tuncel A; Guzel O; Aslan Y; Sezgin T; Bilgin O; Senel C; Atan A
Int Urol Nephrol; 2015 Mar; 47(3):473-7. PubMed ID: 25649031
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the nuclear matrix protein 22 with voided urine cytology in the diagnosis of transitional cell carcinoma of the bladder.
Lekili M; Sener E; Demir MA; Temeltaş G; Müezzinoğlu T; Büyüksu C
Urol Res; 2004 May; 32(2):124-8. PubMed ID: 14685796
[TBL] [Abstract][Full Text] [Related]
3. Role of urinary NMP-22 combined with urine cytology in follow-up surveillance of recurring superficial bladder urothelial carcinoma.
Mansoor I; Calam RR; Al-Khafaji B
Anal Quant Cytol Histol; 2008 Feb; 30(1):25-32. PubMed ID: 18459584
[TBL] [Abstract][Full Text] [Related]
4. NMP-22, urinary cytology, and cystoscopy: a 1 year comparison study.
Schlake A; Crispen PL; Cap AP; Atkinson T; Davenport D; Preston DM
Can J Urol; 2012 Aug; 19(4):6345-50. PubMed ID: 22892257
[TBL] [Abstract][Full Text] [Related]
5. [Non-invasive urine tests in diagnosis and as prognostic markers for urinary bladder carcinoma. Comparison of the BTAstat and NMP 22 tests with immunocytology using monoclonal antibodies against Lewis X and 486p3/12].
Friedrich MG; Hellstern A; Hautmann SH; Noldus I; Huland H
Urologe A; 2003 Apr; 42(4):523-30. PubMed ID: 12715124
[TBL] [Abstract][Full Text] [Related]
6. NMP 22, BTA stat test and cytology in the diagnosis of bladder cancer: a comparative study.
Gutiérrez Baños JL; Rebollo Rodrigo MH; Antolín Juárez FM; Martín García B
Urol Int; 2001; 66(4):185-90. PubMed ID: 11385303
[TBL] [Abstract][Full Text] [Related]
7. Comparative study of NMP-22, telomerase, and BTA in the detection of bladder cancer.
Abd El Gawad IA; Moussa HS; Nasr MI; El Gemae EH; Masooud AM; Ibrahim IK; El Hifnawy NM
J Egypt Natl Canc Inst; 2005 Sep; 17(3):193-202. PubMed ID: 16799657
[TBL] [Abstract][Full Text] [Related]
8. Nuclear matrix protein 22 as adjunct to urine cytology and cystoscopy in follow-up of superficial TCC of urinary bladder.
Gupta NP; Sharma N; Kumar R
Urology; 2009 Mar; 73(3):592-6; discussion 596-7. PubMed ID: 19168205
[TBL] [Abstract][Full Text] [Related]
9. [Determination of NMP-22 as recurrence marker in bladder cancer. Preliminary study].
Pérez García FJ; Escaf Barmadah S; Fernández Gómez JM; Rodríguez Martínez JJ; Martín Benito JL
Arch Esp Urol; 2000 May; 53(4):305-12. PubMed ID: 10900760
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of nuclear matrix protein-22 as a clinical diagnostic marker for bladder cancer.
Chang YH; Wu CH; Lee YL; Huang PH; Kao YL; Shiau MY
Urology; 2004 Oct; 64(4):687-92. PubMed ID: 15491702
[TBL] [Abstract][Full Text] [Related]
11. Comparisons of voided urine cytology, nuclear matrix protein-22 and bladder tumor associated antigen tests for bladder cancer of geriatric male patients in Taiwan, China.
Tsui KH; Chen SM; Wang TM; Juang HH; Chen CL; Sun GH; Chang PL
Asian J Androl; 2007 Sep; 9(5):711-5. PubMed ID: 17712491
[TBL] [Abstract][Full Text] [Related]
12. [NMP-22 in the diagnosis of bladder cancer].
Gutiérrez Baños JL; Rebollo Rodrigo MH; Antolín Juárez F; Martín García B; Hernández Rodríguez R; Portillo Martín JA; Correas Gómez MA; Del Valle Schaan JI; Roca Edreira A; De Diego Rodríguez E; Rado Velázquez MA; Hernández Castrillo A
Actas Urol Esp; 2000 Oct; 24(9):715-20. PubMed ID: 11132442
[TBL] [Abstract][Full Text] [Related]
13. Sensitivity and specificity of NMP-22, telomerase, and BTA in the detection of human bladder cancer.
Landman J; Chang Y; Kavaler E; Droller MJ; Liu BC
Urology; 1998 Sep; 52(3):398-402. PubMed ID: 9730450
[TBL] [Abstract][Full Text] [Related]
14. Comparison of cytology and nuclear matrix protein 22 (NMP 22) for the detection and follow-up of bladder-cancer.
Lahme S; Bichler KH; Feil G; Zumbrägel A; Götz T
Adv Exp Med Biol; 2003; 539(Pt A):111-9. PubMed ID: 15088900
[TBL] [Abstract][Full Text] [Related]
15. [NMP-22 test. Is it useful in the follow-up of patients with superficial bladder tumor?].
Pérez García FJ; Eyo A; Escaf Barmadah S; Fernández Gómez JM
Arch Esp Urol; 2002 Dec; 55(10):1201-8. PubMed ID: 12611217
[TBL] [Abstract][Full Text] [Related]
16. [Comparative study between cystoscopy, urinary cytology, NMP-22 and a new method, bladder chek, in the follow-up of superficial bladder cell carcinoma].
Aguilera Tubet C; Gutiérrez Baños JL; Antolín Juárez F; Rebollo Rodrigo MH; Portillo Martín JA; Ruiz Izquierdo F; Ballestero Diego R; Martín García B
Actas Urol Esp; 2005 Mar; 29(3):252-6. PubMed ID: 15945249
[TBL] [Abstract][Full Text] [Related]
17. Replacing cystoscopy by urine markers in the follow-up of patients with low-risk non-muscle-invasive bladder cancer?-An International Bladder Cancer Network project.
Schmitz-Dräger C; Bonberg N; Pesch B; Todenhöfer T; Sahin S; Behrens T; Brüning T; Schmitz-Dräger BJ
Urol Oncol; 2016 Oct; 34(10):452-9. PubMed ID: 27381893
[TBL] [Abstract][Full Text] [Related]
18. Clinical study of urine NMP 22 (nuclear matrix protein 22) as a tumor marker in urinary epithelial cancer.
Takeuchi Y; Sawada Y; Yabuki D; Masuda E; Satou D; Kuroda K; Tajima M; Sawamura Y; Matsushima M
Aktuelle Urol; 2003 Jul; 34(4):265-6. PubMed ID: 14566681
[TBL] [Abstract][Full Text] [Related]
19. Performance of nuclear matrix protein 22 urine marker and voided urine cytology in the detection of urinary bladder tumors.
Smrkolj T; Mihelič M; Sedlar A; Sterle I; Osredkar J; Sedmak B
Clin Chem Lab Med; 2011 Feb; 49(2):311-6. PubMed ID: 21118051
[TBL] [Abstract][Full Text] [Related]
20. Voided urinary cytology in bladder cancer: is it time to review the indications?
Talwar R; Sinha T; Karan SC; Doddamani D; Sandhu A; Sethi GS; Srivastava A; Narang V; Agarwal A; Adhlakha N
Urology; 2007 Aug; 70(2):267-71. PubMed ID: 17826487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
